CHAMPS HF - We All Can do Better!

CHAMPS HF - We All Can do Better! Posted By:
...

Many of us manage patients with heart failure with a reduced ejection fraction, or HFrEF. The management of this patient population is complex, and most patients usually have more active problems than just heart failure. That is why it is not a surprise that a recent study showed that we as practitioners are not doing as well as we could when it comes to following the appropriate guidelines for heart failure.

According to the CHAMP-HF registry, many patients are not being prescribed the appropriate medications that are recommended within the guidelines published by the American Heart Association (AHA) and American College of Cardiology (ACC). The medications that were studied to determine their use and compliance with the guidelines were angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), beta blockers, angiotensin receptor/neprilysin inhibitors (ARNI), and mineralocorticoid receptor antagonists. The study showed a large percentage of eligible patients were either not placed on the appropriate medication, not given the target dose, or not prescribed medication at all. While ACE inhibitors and beta blockers were better than the other classes of medications, the data showed that there were significant gaps in coverage for medications that would benefit patients with heart failure. The conclusions were simple: patients who qualify for these medications should be placed on them when appropriate, and practitioners are encouraged to follow the AHA/ACC guidelines.

We all want our patients to succeed. However, following the recommended guidelines must be done in order to achieve the best possible outcomes for this complicated disease. We owe it to our patients to do better!

Reference
  • Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351-366.

Share

Filed under: Preventive Medicine , Cardiometabolic

Related
Atrial Fibrillation: Optimizing Outcomes by Addressing Social Determinants of Health and Implicit Bias

Atrial Fibrillation: Optimizing Outcomes by Addres ...

Atrial fibrillation (AF) is the most common sustained arrhythmia diagnosed, and its prevalence is ex ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
My Experience With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes

My Experience With GLP-1 Receptor Agonists in Pati ...

When considering the benefits of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) for our pat ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Dietary Sodium Restriction in Patients With Heart Failure

Dietary Sodium Restriction in Patients With Heart ...

There are about 6.2 million adults in the United States living with heart failure (HF), according to ...

Filed under: Cardiometabolic, Pulmonary Medicine


Continue Reading
Bleeding Risk with Apixaban and Systemic Fluconazole Use

Bleeding Risk with Apixaban and Systemic Fluconazo ...

We, as healthcare professionals, are aware that we must check for drug interactions in our patients ...

Filed under: Cardiometabolic, Pulmonary Medicine


Continue Reading
Cardiovascular Risk in Rheumatic Inflammatory Disease

Cardiovascular Risk in Rheumatic Inflammatory Dise ...

It is well documented that those with rheumatic inflammatory diseases have an increased risk of card ...

Filed under: Cardiometabolic, Rheumatology


Continue Reading
The Latest on Heart Failure: Clinical Trials Summary

The Latest on Heart Failure: Clinical Trials Summa ...

Too often, we are faced with hectic workdays that lead into hectic home lives—when we clock ou ...

Filed under: Cardiometabolic


Continue Reading